This is an expected operational update with no data readout. Monitor for topline Phase 2b results (likely 12+ months away) and any capital markets activity given the company's cash burn and prediction-markets treasury strategy.
Price Chart
Executive Summary
Enlivex dosed the first U.S. patient in its Phase 2b trial of Allocetra for knee osteoarthritis, following FDA IND clearance in March 2026 and DKMA approval in April 2026. This is a routine clinical milestone for a pre-revenue biotech — no financial data or efficacy results were disclosed, and the event does not change the binary risk profile of the program.
Key Facts
- First U.S. patient dosed in Phase 2b trial of Allocetra for moderate-to-severe age-related knee osteoarthritis
- Trial is global, randomized, double-blind, placebo-controlled, enrolling in the U.S., Denmark, and Poland
- Key endpoints: pain and physical function change from baseline at 3 and 6 months
- FDA IND clearance received March 2026; DKMA approval received April 2026
- No financial figures, guidance, or efficacy data disclosed in the filing
Financial Impact
No financial data reported; pre-revenue clinical-stage company
Risk Factors
- Phase 2b may fail to replicate Phase 1/2a efficacy signals
- Company's novel treasury strategy (RAIN token) introduces idiosyncratic volatility uncorrelated with clinical progress
- Pre-revenue biotech with no approved products; dilution risk from future financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-058130 |
| Document: ea0291229-6k_enlivex.htm | 0001213900-26-058130 |
| Document: 0001213900-26-058130-index-headers.html | 0001213900-26-058130 |
| Document: 0001213900-26-058130-index.html | 0001213900-26-058130 |
| Document: 0001213900-26-058130.txt | 0001213900-26-058130 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.1734 | awaiting T+5 | — | $0.1730 (+0.23%) |
Oct 22, 2026 5d ago | 6-K | $0.1734 | awaiting T+5 | — | $0.1730 (−0.23%) |
Oct 22, 2026 5d ago | Press Release | $0.1734 | awaiting T+5 | — | $0.1730 (−0.23%) |
Oct 19, 2026 8d ago | 6-K | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | $0.1730 (+16.43%) |
Oct 19, 2026 8d ago | Press Release | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | $0.1730 (+16.43%) |
Sep 25, 2026 4w ago | 6-K | $0.5140 $0.3620 | ▼ −29.57% | ▼ −30.78% | $0.1730 (−66.34%) |
Sep 22, 2026 5w ago | 6-K | $0.6464 $0.4801 | ▼ −25.73% | ▼ −24.54% | $0.1730 (−73.24%) |
Aug 14, 2026 10w ago | EFFECT | $1.58 $1.47 | ▼ −6.96% | ▼ −5.59% | $0.1730 (−89.05%) |
Jul 30, 2026 12w ago | 6-K | $1.95 $1.98 | ▲ +1.54% | ▼ −2.08% | $0.1730 (−91.13%) |
Jul 29, 2026 12w ago | 6-K | $2.25 $2.18 | ▼ −3.11% | ▼ −8.64% | $0.1730 (−92.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers